Litcius/Paper detail

177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response

Nasrin Raeisi, Amin Saber Tanha, Mohammad Hossein Gozashti, Zahra Kiamanesh, Kamran Aryana

2025Clinical Nuclear Medicine9 citationsDOI

Abstract

We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after undergoing a single cycle of 177Lu-FAPI-2286 therapy. A pretreatment 99mTc-FAPI-46 scan showed diffuse uptake throughout both lungs and subsequent serial post-treatment scans demonstrated sustained uptake in pulmonary metastases. After treatment, there was a significant decline in serum thyroglobulin levels, accompanied by a remarkable improvement in symptoms, leading to near-complete resolution. This case highlights the potential of 177Lu-FAPI-2286 therapy as an effective treatment option for RAIR PTC patients.

Topics & Concepts

MedicineThyroid carcinomaRefractory (planetary science)IodineRadionuclide therapyCarcinomaThyroidThyroglobulinNuclear medicineRadiologyInternal medicineUrologyGastroenterologyMetallurgyPhysicsAstrobiologyMaterials sciencePeptidase Inhibition and AnalysisProtease and Inhibitor MechanismsRadiopharmaceutical Chemistry and Applications
177Lu-FAPI-2286 Therapy in a Patient With Radio-iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response | Litcius